• Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas

  NCT04425967

  Active, not recruitingInterventionalNot ApplicableUpdated Jan 20, 2026
• Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma

  NCT07265661

  Not yet recruitingInterventionalNot ApplicableUpdated Jan 6, 2026
• Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities

  NCT06760221

  RecruitingInterventionalNot ApplicableUpdated Jan 6, 2025
• 5-Day Preoperative Radiation for Soft Tissue Sarcoma

  NCT06087861

  RecruitingInterventionalPhase 2Updated Jun 10, 2026
• Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk

  NCT03819985

  Active, not recruitingInterventionalPhase 2Updated Mar 5, 2026
• Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk

  NCT04562480

  Active, not recruitingInterventionalPhase 2Updated Feb 4, 2026

ClinicalTrials.gov ID

NCT07071727

Lead Sponsor

The Netherlands Cancer InstituteOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

150Estimated

Last Update Posted

Feb 19, 2026Actual

Start Date

Dec 11, 2025Actual

Primary Completion Date

Nov 1, 2028Estimated

Completion Date

Nov 1, 2033Estimated

Official Title

Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas; a Second Randomized Phase II Clinical Trial

Brief Summary

Based upon the preliminary data derived from first SCOPES clinical trial and the results of patients treated during the recent COVID-19 pandemic, patients with soft tissue sarcomas (STS) can be preoperatively irradiated in a modestly hypofractionated schedule of 14 x 3 Gy. From a toxicity and efficacy point of view, this regimen equals the outcomes after a conventionally fractionated regimen of 25 x 2 Gy in five weeks. Moreover, the rationale for investigating (modest) hypofractionation in the clinic comes both from a logistic point of view (patient convenience and a lower pressure on radiotherapy equipment), form prior phase II clinical evidence and from (cellular) radiobiological observations. There is phase II trial evidence suggesting that even more (ultra-) hypofractionation to 5 x 6 Gy is also safe and effective. Within this study, patients will be randomized to receive either the modestly hypofractionated conventional schedule of 14 x 3 Gy or an even shorter preoperative regimen of 5 x 6 Gy, in the hypothesis that both the postoperative wound complication rate until 120 days after surgery, as well as the local control probability at two years are comparable in both arms.

• Sarcoma of Soft Tissue
• Sarcoma
• Sarcoma, Soft Tissue

• Preoperative radiotherapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Histologically confirmed intermediate to high grade soft tissue sarcoma localized to the head and neck area, to the trunk and chest wall or to the extremities, for which the standard treatment is a combination of and radiotherapy and surgery (deep seated and/or ≥ 5cm in largest tumor diameter and/or an anticipated close resection margin and/or grade II/III according to the FNCLCC definition);
• Absence of regional and/or distant disease. Patients must be staged by at least a CT scan of the chest. Staging may also be performed by FDG-PET scanning and/or total body MRI scans;
• WHO Performance Status ≤ 2;
• Able and willing to undergo preoperative radiotherapy;
• Able and willing to undergo definitive surgery;
• Able and willing to comply with regular follow-up visits;
• Able and willing to complete patient reported outcome questionnaires (health-related quality of life and cost effectiveness);
• Able and willing to undergo randomization;
• Age ≥ 18 years;
• Signed written informed consent.

Exclusion Criteria:

• Prior malignancies; except another malignancy and disease-free for ≥ 5 years, or completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma;
• Patients with locally recurrent sarcomas, regardless of the management of the first sarcoma diagnosis;
• Ewing sarcoma and other PNET family tumors, rhabdomyosarcomas (both pediatric and adult), osteosarcomas;
• Myxoid liposarcomas, because they have shown to be exquisitely sensitive to a lower dose of radiation as compared to the 2 regimens tested in this trial.
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
• Female patients who are pregnant;
• Intention to perform an isolated limb perfusion, instead of a tumor resection;
• Neoadjuvant chemotherapy both before and after radiotherapy.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

The Netherlands Cancer InstituteOTHER

Collaborators

Radboud University Medical CenterOTHER

University Medical Center GroningenOTHER

Leiden University Medical CenterOTHER

Amsterdam UMCOTHER

Maastro Clinic, The NetherlandsOTHER

b.v.balgobind@amsterdamumc.nl+31 20 5669111

a.d.g.krol@lumc.nl+31 71 526 9111